Aczone 7.5% (dapsone 7.5 gel) is filed as Topical Anti-Acne. The sections below restate public label fields stored for this profile.
ACZONE ® (dapsone) Gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ACZONE ® Gel, 7.5%, is a sulfone indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
The mechanism of action of dapsone gel in treating acne vulgaris is not known.
Methemoglobinemia: Cases of methemoglobinemia have been reported. • Hemolysis: Some patients with Glucose-6-phosphate Dehydrogenase (G6PD) deficiency using topical dapsone developed laboratory changes suggestive of hemolysis. • Cases of methemoglobinemia, with resultant hospitalization, have been reported postmarketing in association with twice daily dapsone gel, 5%, treatment. • Signs and symptoms of methemoglobinemia may be delayed some hours after exposure. • Dapsone can cause elevated methemoglobin levels particularly in conjunction with methemoglobin-inducing agents. • Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia.
None.
For topical use only. • After the skin is gently washed and patted dry, apply approximately a pea-sized amount of ACZONE Gel, 7.5%, in a thin layer to the entire face once daily. • If there is no improvement after 12 weeks, treatment with ACZONE Gel, 7.5% should be reassessed. • Apply once daily.
No formal drug-drug interaction studies were conducted with ACZONE Gel, 7.5%. • Trimethoprim/sulfamethoxazole (TMP/SMX) increases the systemic level of dapsone and its metabolites. • Topical benzoyl peroxide used at the same time as ACZONE Gel, 7.5% may result in temporary local yellow or orange skin discoloration. • A drug-drug interaction study evaluated the effect of the use of dapsone gel, 5% in combination with double strength (160 mg/800 mg) trimethoprim-sulfamethoxazole (TMP/SMX). • Topical application of dapsone gel followed by benzoyl peroxide in patients with acne vulgaris may result in a temporary local yellow or orange discoloration of the skin and facial hair.
According to its FDA label, Aczone 7.5% (dapsone 7.5 gel) is approved for: ACZONE ® (dapsone) Gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.. ACZONE ® Gel, 7.5%, is a sulfone indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. For medical advice, please talk to your prescriber or pharmacist.
Aczone 7.5% (dapsone 7.5 gel) belongs to the Topical Anti-Acne class of medications.
Yes. A generic version of Aczone 7.5% (dapsone 7.5 gel) is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Aczone 7.5% (dapsone 7.5 gel) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Aczone 7.5% (dapsone 7.5 gel) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Aczone 7.5% (dapsone 7.5 gel) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA label states: "Storage: Store at 20°C-25°C (68°F-77°F), excursions permitted to 15°C-30°C (59°F-86°F)." Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…